文献速递瘢痕与激光创面修复

脂肪酶A作为增生性瘢痕脂代谢相关生物标志物与治疗靶点

Lipase A as a lipid metabolism-related biomarker and therapeutic target in hypertrophic scars.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2025-12-10

该研究通过分析增生性瘢痕与正常成纤维细胞的转录组数据集,鉴定出64个差异表达的脂代谢相关基因,并以LASSO回归锁定脂肪酶A(LIPA)为核心枢纽基因。ROC分析证实LIPA具有较高诊断准确性,体外实验显示TGF-β1刺激后LIPA在mRNA和蛋白水平一致上调,沉默LIPA可显著抑制成纤维细胞增殖与迁移。分子对接显示倍他米松与LIPA结合最强,提示其作为HS脂代谢相关生物标志物与治疗靶点的潜力。

要点

  • LIPA在增生性瘢痕成纤维细胞中mRNA和蛋白水平一致上调,ROC分析示诊断准确性较高。
  • 沉默LIPA可显著抑制TGF-β1刺激的成纤维细胞增殖与迁移。
  • 分子对接中倍他米松与LIPA结合最强,提示潜在药理靶向策略。

核心结论

  • LIPA被确立为增生性瘢痕的脂代谢相关生物标志物与治疗靶点。
  • 研究提供连接脂代谢与瘢痕进展的机制框架,支持靶向代谢通路的精准治疗策略。

研究设计与样本

  • 分析增生性瘢痕与正常成纤维细胞的转录组数据集。
  • 采用LASSO回归筛选枢纽基因,ROC分析评估诊断准确性。
  • 在TGF-β1刺激的成纤维细胞中进行mRNA与蛋白水平实验验证及功能实验。
  • 对五种常用增生性瘢痕药物进行分子对接分析。

主要发现

  • 鉴定出64个差异表达的脂代谢相关基因,富集于亚油酸和鞘脂代谢通路。
  • LASSO回归锁定LIPA为核心枢纽基因,ROC分析证实其诊断准确性较高。
  • TGF-β1刺激的成纤维细胞中LIPA在mRNA和蛋白水平一致上调。
  • 沉默LIPA显著抑制成纤维细胞增殖与迁移。
  • 分子对接显示倍他米松与LIPA结合最强。

关键数值与推荐

  • 差异表达脂代谢相关基因共64个,富集于亚油酸和鞘脂代谢通路。
  • 分子对接涉及五种常用HS药物:5-氟尿嘧啶、倍他米松、咪喹莫特、曲安奈德和维拉帕米。
  • 倍他米松被鉴定为与LIPA结合最强的化合物。

临床怎么用

  • LIPA可作为增生性瘢痕的候选诊断生物标志物。
  • 靶向LIPA或脂代谢通路可能成为增生性瘢痕的精准治疗策略。
  • 倍他米松与LIPA的强结合提示其潜在药理靶向价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertrophic scar (HS) is a pathological outcome of wound healing, characterized by excessive fibroblast activation and abnormal extracellular matrix deposition. Recent studies indicate that metabolic changes, particularly in lipid pathways, are involved in fibroblast regulation and scar progression. Current treatments often show limited efficacy and high recurrence. To better understand the underlying mechanisms, we analyzed transcriptomic datasets of HS and normal fibroblasts. We identified 64 lipid metabolism-related genes that were differentially expressed, with enrichment in the linoleic acid and sphingolipid metabolic pathways. LASSO regression highlighted lipase A (LIPA) as a key hub gene. Receiver operating characteristic analysis confirmed the high diagnostic accuracy of LIPA. Experimental validation in TGF-β1-stimulated fibroblasts demonstrated consistent upregulation of expression at both mRNA and protein levels. Functional assays showed that silencing LIPA significantly inhibited fibroblast proliferation and migration. Furthermore, molecular docking with five commonly used HS drugs-5-fluorouracil, betamethasone, imiquimod, triamcinolone, and verapamil-identified betamethasone as the strongest binding compound for LIPA, suggesting potential pharmacological targeting. Collectively, these findings establish LIPA as a lipid metabolism-related biomarker and therapeutic target in HS. This study provides a mechanistic framework linking lipid metabolism to scar progression and supports strategies targeting metabolic pathways for precise HS therapy.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhou X, Chen J, et al. Lipase A as a lipid metabolism-related biomarker and therapeutic target in hypertrophic scars. J Plast Reconstr Aesthet Surg. 2025. PMID: 41442790. doi:10.1016/j.bjps.2025.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。